Mangoceuticals announces that it has received a Notice of Allowance for Japanese Patent Application No. 2021-545824, originally applied for by Intramont Technologies.This significant milestone follows MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies. The Notice of Allowance covers the proprietary formulation and application methods designed to combat a wide range of infections, including common colds, respiratory diseases, and orally transmitted infections such as human papillomavirus HPV . The US patent was initially applied for by Intramont and subsequently acquired by MangoRx on April 24, 2024, further expanding the global protection for its groundbreaking preventive care technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
- Mangoceuticals completes first batch of mango ED products for LATAM
- Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
- MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
- Mangoceuticals engages Crakmedia for digital marketing efforts